CAR-T Cell Therapy Market Demand, Size and Competitive Analysis | TechSci Research

Global CAR-T Cell Therapy Market was valued at USD 2.87 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 22.17% through 2029. <table><tr><td>Pages</td><td>182</td></tr> <tr><td>Market Size</td><td>2023: USD 2.87 Billion</td></tr> <tr><td>Forecast Market Size</td><td>2029: USD 9.46 Billion</td></tr> <tr><td>CAGR</td><td>2024-2029: 22.17%</td></tr> <tr><td>Fastest Growing Segment</td><td>Acute Lymphoblastic Leukemia (ALL)</td></tr> <tr><td>Largest Market</td><td>North America</td></tr> <tr><td>Key Players</td><td>1.Gilead Sciences, Inc.2.Novartis AG3.Bristol-Myers Squibb Company4.AbbVie Inc.5.Cellectis SA6.Amgen Inc.7.Pfizer Inc8.Merck KgaA9.Intellia Therapeutics, Inc.10.Johnson & Johnson</td></tr> </table>

全球CAR-T细胞疗法市场在2023年达到价值28.7亿美元，预计在预测期内将实现强劲增长，复合年增长率(CAGR)预计将达到22.17%，至2029年将达到94.6亿美元。详见表格：
<table><tr><td>页数</td><td>182</td></tr>
<tr><td>市场规模</td><td>2023年：28.7亿美元</td></tr>
<tr><td>预测市场规模</td><td>2029年：94.6亿美元</td></tr>
<tr><td>复合年增长率(CAGR)</td><td>2024-2029年：22.17%</td></tr>
<tr><td>增长最快的细分市场</td><td>急性淋巴细胞白血病(ALL)</td></tr>
<tr><td>最大市场</td><td>北美</td></tr>
<tr><td>主要参与者</td><td>1.Gilead Sciences, Inc.2.Novartis AG3.Bristol-Myers Squibb Company4.AbbVie Inc.5.Cellectis SA6.Amgen Inc.7.Pfizer Inc8.Merck KgaA9.Intellia Therapeutics, Inc.10.Johnson & Johnson</td></tr>
</table>